Recent advances in the treatment of pancreatic cancer

被引：0
作者：
Yongsu Ma [1 ]
Fusheng Zhang [1 ]
Yinmo Yang [1 ]
机构：
[1] Peking University First Hospital,Department of Hepatobiliary and Pancreatic Surgery
来源：
Holistic Integrative Oncology | / 3卷 / 1期
关键词：
Pancreatic cancer; Neoadjuvant therapy; Chemotherapy; Targeted therapy; Immunotherapy;
D O I：
10.1007/s44178-024-00089-6
中图分类号：
学科分类号：
摘要：
Pancreatic cancer (PC) is one of the most aggressive gastrointestinal malignancies, characterized by rapid progression and early onset of metastasis, leading to a dismal prognosis for patients. In the recent past, substantial progress has been conducted recently in managing PC, encompassing various treatment modalities such as chemotherapy, neoadjuvant therapy, targeted therapy, and immunotherapy. Particularly in 2023, several noteworthy studies have contributed to optimizing neoadjuvant treatment regimens and exploring novel approaches that involve targeted therapies and immunotherapies for PC. These advancements hold promise for improving overall survival outcomes and enhancing quality of life for patients with pancreatic cancer. This commentary summarizes the new advances in systemic therapy for pancreatic cancer in 2023.
引用
收藏
相关论文
共 129 条
[1]  
Halbrook CJ(2023)Pancreatic cancer: Advances and challenges Cell 186 1729-1754
[2]  
Lyssiotis CA(2023)Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer New Eng J Med 388 33-43
[3]  
Pasca di Magliano M(2022)Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor Nat Med 28 2171-82
[4]  
Maitra A(2021)KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments J Thorac Oncol 16 1321-32
[5]  
Strickler JH(2020)Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma J Hematol Oncol 13 130-327
[6]  
Satake H(2019)Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer Eng J Med 381 317-97
[7]  
George TJ(2023)APOLLO: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2 or PALB2 mutation—ECOG-ACRIN EA2192 J Clin Oncol 41 TPS763-100
[8]  
Yaeger R(2023)Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort Eur J Cancer 188 90-124
[9]  
Hollebecque A(2023)Shen, CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer J Hematol Oncol 16 102-81
[10]  
Garrido-Laguna I(2023)Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group Ann Oncol 34 91-168
12345678910